<html>
<head>
<title>Re: PRIME and FDA</title>
<link rel="important stylesheet" href="chrome://messenger/skin/messageBody.css">
</head>
<body>
<table border=0 cellspacing=0 cellpadding=0 width="100%" class="header-part1"><tr><td><b>Subject: </b>Re: PRIME and FDA</td></tr><tr><td><b>From: </b>"Bill Donner" <bdonner@medcommons.org></td></tr><tr><td><b>Date: </b>Fri, 16 Jan 2004 11:54:56 -0500</td></tr></table><table border=0 cellspacing=0 cellpadding=0 width="100%" class="header-part2"><tr><td><b>To: </b>"Adrian Gropper" <agropper@medcommons.org>,	<sdoyle@medcommons.org></td></tr></table><br>
<div class="moz-text-plain"><pre wrap>I think all communications with PRIME and similar organizations should go
into the archive
----- Original Message ----- 
From: "Adrian Gropper" <a class="moz-txt-link-rfc2396E" href="mailto:agropper@medcommons.org">&lt;agropper@medcommons.org&gt;</a>
To: "Erickson, Bradley J., M.D." <a class="moz-txt-link-rfc2396E" href="mailto:bje@mayo.edu">&lt;bje@mayo.edu&gt;</a>
Cc: "'Herman'" <a class="moz-txt-link-rfc2396E" href="mailto:herman@otechimg.com">&lt;herman@otechimg.com&gt;</a>; <a class="moz-txt-link-rfc2396E" href="mailto:dclunie@dclunie.com">&lt;dclunie@dclunie.com&gt;</a>;
<a class="moz-txt-link-rfc2396E" href="mailto:dsc@radiology.northwestern.edu">&lt;dsc@radiology.northwestern.edu&gt;</a>; "'Horii Steve'"
<a class="moz-txt-link-rfc2396E" href="mailto:Steve.Horii@uphs.upenn.edu">&lt;Steve.Horii@uphs.upenn.edu&gt;</a>; "'Langer Steve G. Ph.D. '"
<a class="moz-txt-link-rfc2396E" href="mailto:Langer.Steve@mayo.edu">&lt;Langer.Steve@mayo.edu&gt;</a>; "''Siegel Eliot ' '" <a class="moz-txt-link-rfc2396E" href="mailto:esiegel@umaryland.edu">&lt;esiegel@umaryland.edu&gt;</a>;
"''Avrin David ' '" <a class="moz-txt-link-rfc2396E" href="mailto:david.avrin@hsc.utah.edu">&lt;david.avrin@hsc.utah.edu&gt;</a>; "''Brian Bartholmai ' '"
<a class="moz-txt-link-rfc2396E" href="mailto:Bartholmai.Brian@mayo.edu">&lt;Bartholmai.Brian@mayo.edu&gt;</a>; "''Bruce Reiner ' '" <a class="moz-txt-link-rfc2396E" href="mailto:breiner1@comcast.net">&lt;breiner1@comcast.net&gt;</a>;
"'Channin David (NMH)'" <a class="moz-txt-link-rfc2396E" href="mailto:dchannin@nmh.org">&lt;dchannin@nmh.org&gt;</a>; "''Curt Langlotz (Langlotz Curt)
' '" <a class="moz-txt-link-rfc2396E" href="mailto:cl208e@nih.gov">&lt;cl208e@nih.gov&gt;</a>; "''Daniel J. Valentino ' '"
<a class="moz-txt-link-rfc2396E" href="mailto:DValentino@mednet.ucla.edu">&lt;DValentino@mednet.ucla.edu&gt;</a>; "''David W Piraino ' '" <a class="moz-txt-link-rfc2396E" href="mailto:piraind@ccf.org">&lt;piraind@ccf.org&gt;</a>;
"''Gary York ' '" <a class="moz-txt-link-rfc2396E" href="mailto:gyork@emageon.com">&lt;gyork@emageon.com&gt;</a>; "''John Pearson ' '"
<a class="moz-txt-link-rfc2396E" href="mailto:john.pearson@scr.siemens.com">&lt;john.pearson@scr.siemens.com&gt;</a>; "''Katherine Andriole (Andriole Katherine) '
'" <a class="moz-txt-link-rfc2396E" href="mailto:kathy.andriole@radiology.ucsf.edu">&lt;kathy.andriole@radiology.ucsf.edu&gt;</a>; "''Lorensen Bill ' '"
<a class="moz-txt-link-rfc2396E" href="mailto:lorensen@crd.ge.com">&lt;lorensen@crd.ge.com&gt;</a>; "''Moore Steve ' '" <a class="moz-txt-link-rfc2396E" href="mailto:MooreS@mir.wustl.edu">&lt;MooreS@mir.wustl.edu&gt;</a>;
"''Mortimer Bill ' '" <a class="moz-txt-link-rfc2396E" href="mailto:billm@merge.com">&lt;billm@merge.com&gt;</a>; "''Nagy Paul ' '" <a class="moz-txt-link-rfc2396E" href="mailto:pnagy@mcw.edu">&lt;pnagy@mcw.edu&gt;</a>;
"''Ratib Osman ' '" <a class="moz-txt-link-rfc2396E" href="mailto:ORatib@mednet.ucla.edu">&lt;ORatib@mednet.ucla.edu&gt;</a>; "''Ronald Summers ' '"
<a class="moz-txt-link-rfc2396E" href="mailto:rms@nih.gov">&lt;rms@nih.gov&gt;</a>; "''Seibert Tony ' '" <a class="moz-txt-link-rfc2396E" href="mailto:jaseibert@ucdavis.edu">&lt;jaseibert@ucdavis.edu&gt;</a>; "''Ryan William
J. ' '" <a class="moz-txt-link-rfc2396E" href="mailto:ryan.william@mayo.edu">&lt;ryan.william@mayo.edu&gt;</a>; "''Brian ' '"
<a class="moz-txt-link-rfc2396E" href="mailto:brian@rosenthaltechnologies.com">&lt;brian@rosenthaltechnologies.com&gt;</a>; "''Doyle Sean ' '"
<a class="moz-txt-link-rfc2396E" href="mailto:sdoyle@medcommons.org">&lt;sdoyle@medcommons.org&gt;</a>; "''Haramati Nogah ' '" <a class="moz-txt-link-rfc2396E" href="mailto:nharamat@montefiore.org">&lt;nharamat@montefiore.org&gt;</a>;
"''Joseph Dal Molin ' '" <a class="moz-txt-link-rfc2396E" href="mailto:dalmolin@e-cology.ca">&lt;dalmolin@e-cology.ca&gt;</a>; "''Morin Richard L. PhD. '
'" <a class="moz-txt-link-rfc2396E" href="mailto:morin.richard@mayo.edu">&lt;morin.richard@mayo.edu&gt;</a>; "''Persons Kenneth R. ' '"
<a class="moz-txt-link-rfc2396E" href="mailto:krpersons@mayo.edu">&lt;krpersons@mayo.edu&gt;</a>; "'Sensmeier Joyce'" <a class="moz-txt-link-rfc2396E" href="mailto:JSensmeier@himss.org">&lt;JSensmeier@himss.org&gt;</a>;
"'Christopher Carr'" <a class="moz-txt-link-rfc2396E" href="mailto:carr@rsna.org">&lt;carr@rsna.org&gt;</a>
Sent: Thursday, January 15, 2004 11:21 PM
Subject: Re: PRIME and FDA


Brad

The most important elements of an FDA-compliant process are Design
Controls and Corrective and Preventive Action (CAPA) procedures. Design
Controls impose some formality on the specification of requirements,
design and implementation and require formal design review meetings.
CAPA procedures are not unlike a bug tracking system. Throw in some
formal risk analysis and procedures to track the impact of design
changes on risks and you have most of the requirements for FDA
compliance as far as the engineering and coding are concerned.

There are other parts to FDA including testing and management
formalisms  as well as the 510[k] filing itself - but these added
requirements do
not impact the coding directly.

MedCommons is configuring and enhancing some open source tools to
assist  with Design Controls and CAPA and will return these tools to the
community. We're working on this now, but do not have a timetable yet.

Adrian

Erickson, Bradley J., M.D. wrote:

</pre><blockquote type=cite><pre wrap>Herman,
I appreciate your thoughtful comments. However, I would tend to disagree,
</pre></blockquote><pre wrap><!---->or view them in a different way. To be sure, I am not saying we can
compromise on quality (who would). However, until the majority of people who
are going to be doing the work weigh in, it is hard to say what development
method is possible. I would rather have solid code that advances the field
that is not FDA compliant, than only a few pieces that are FDA approved. I
am also not convinced that good code would not be useful. To my knowledge,
the Mallinkrodt CTN code was not FDA certified, but made its way into many
commercial/FDA approved products. I think if vendors really want this code
to be something they can take as is (e.g. already FDA approved) they will
have to support the effort in the form of training on how to be FDA
compliant, and perhaps provide resources to do the FDA approval.
Vendors--what do you think??
</pre><blockquote type=cite><pre wrap>But that does raise an intersting question: most of the people on this
</pre></blockquote><pre wrap><!---->list are leaders, and not necessarily coders. Would people throw in their
thoughts about who will be doing this (e.g. is it feasible to train them on
FDA-acceptable methods), and how do we go about recruiting them, and
training them. I know some people are contemplating grant applications to
fund development of pieces that might fit in. Developers:     Is FDA one of
your goals/commitments?
</pre><blockquote type=cite><pre wrap>Thanks
Brad

-----Original Message-----
From: Herman [<a class="moz-txt-link-freetext" href="mailto:herman@otechimg.com">mailto:herman@otechimg.com</a>]
Sent: Tuesday, January 06, 2004 11:51 PM

To all:

Re FDA: The key requirement for 510(k) filing is that a quality system has
</pre></blockquote><pre wrap><!---->been followed during the implementation and design. That is good engineering
practice anyway, so why not just make that a requirement? Whether or not to
file can than be decided later on. I think it is a pity to rule it out to
start with. The cost of the filing is relatively small (typically less than
US$15k including consulting and filing fees), something I would think we
might be able to get funding for if needed.
</pre><blockquote type=cite><pre wrap>
There are some issues as soon as you have approval, for example, if there
</pre></blockquote><pre wrap><!---->is a major bug, who does the client report it to, or who does the FDA call
if they get a complaint? (customer complaint procedures are a requirement
for medical devices). These are all issues that can be addressed I think.
</pre><blockquote type=cite><pre wrap>
Herman Oosterwijk




</pre></blockquote><pre wrap><!---->

</pre></div></body>
</html>
